Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

2 Stocks That Raised Their Guidance in July


One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ: PEP). Both businesses are showing strong growth despite inflation, and expect more of the same as 2023 rolls on. Are these stocks no-brainer buys given their outlooks, or have investors already been pricing in much of the growth ahead?

Drugmaker Novartis released its second-quarter earnings earlier this month. The company's Q2 revenue rose by 7% to $13.6 billion. Novartis also reported strong earnings per share (EPS) of $1.11, which was 44% higher than the $0.77 it posted a year earlier.

As a result of the encouraging performance through the first half of the year, management also bumped up its projections for the year, expecting the company's top line to generate high-single-digit growth, an increase over the mid-single-digit growth it previously projected. Novartis expects this growth to come from both its innovative medicines and Sandoz, its generic and biosimilar business it plans to spin off before the end of this year. Either way, Novartis is expecting a stronger year in 2023.

Continue reading


Source Fool.com

Novartis AG ADR Aktie

134,00 €
0,00 %
Konstant: Der Novartis AG ADR Kurs hält sein Niveau ohne Veränderung seit gestern.
Die Community zeigt eine Präferenz für Buy-Einschätzungen bei Novartis AG ADR.
Das Community-Kursziel von 150 € für Novartis AG ADR deutet auf ein leicht positives Wachstumspotenzial gegenüber 134.0 € hin.
Like: 0
NVS
Teilen

Kommentare